Analysts predict that LHC Group, Inc. (NASDAQ:LHCG) will report earnings of $1.00 per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for LHC Group’s earnings, with the highest EPS estimate coming in at $1.02 and the lowest estimate coming in at $0.98. LHC Group reported earnings of $0.84 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 19%. The firm is expected to announce its next earnings report on Wednesday, August 7th.
According to Zacks, analysts expect that LHC Group will report full-year earnings of $4.30 per share for the current financial year, with EPS estimates ranging from $4.29 to $4.32. For the next financial year, analysts forecast that the company will report earnings of $4.57 per share, with EPS estimates ranging from $4.37 to $4.73. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover LHC Group.
LHC Group (NASDAQ:LHCG) last issued its earnings results on Wednesday, May 8th. The health services provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.08. The business had revenue of $502.59 million during the quarter, compared to analyst estimates of $511.16 million. LHC Group had a return on equity of 8.43% and a net margin of 3.83%.
LHCG has been the subject of a number of recent research reports. BidaskClub upgraded LHC Group from a “hold” rating to a “buy” rating in a research note on Tuesday, April 30th. UBS Group set a $133.00 target price on LHC Group and gave the company a “buy” rating in a research note on Friday, May 10th. SunTrust Banks upped their target price on LHC Group to $130.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Royal Bank of Canada upped their target price on LHC Group to $130.00 and gave the company an “outperform” rating in a research note on Monday, May 13th. Finally, Robert W. Baird upped their target price on LHC Group from $98.00 to $120.00 and gave the company a “neutral” rating in a research note on Monday, March 4th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $120.58.
Shares of NASDAQ LHCG traded up $2.60 during trading hours on Monday, reaching $117.24. The stock had a trading volume of 10,461 shares, compared to its average volume of 178,803. The company has a current ratio of 1.57, a quick ratio of 1.57 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $3.65 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 1.95 and a beta of 0.83. LHC Group has a twelve month low of $80.84 and a twelve month high of $122.20.
In other LHC Group news, COO Donald Dwayne Stelly sold 448 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $120.00, for a total value of $53,760.00. Following the sale, the chief operating officer now directly owns 91,252 shares in the company, valued at $10,950,240. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronald T. Nixon sold 12,000 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $117.20, for a total value of $1,406,400.00. Following the completion of the sale, the director now owns 29,100 shares in the company, valued at $3,410,520. The disclosure for this sale can be found here. Insiders sold 62,991 shares of company stock worth $7,134,055 over the last quarter. Company insiders own 5.20% of the company’s stock.
A number of large investors have recently made changes to their positions in LHCG. Parallel Advisors LLC boosted its holdings in LHC Group by 790.0% in the first quarter. Parallel Advisors LLC now owns 267 shares of the health services provider’s stock valued at $30,000 after acquiring an additional 237 shares during the last quarter. Sageworth Trust Co bought a new position in LHC Group in the first quarter valued at about $36,000. Quadrant Capital Group LLC boosted its holdings in LHC Group by 1,045.7% in the first quarter. Quadrant Capital Group LLC now owns 527 shares of the health services provider’s stock valued at $57,000 after acquiring an additional 481 shares during the last quarter. Meeder Asset Management Inc. bought a new position in LHC Group in the first quarter valued at about $68,000. Finally, Private Capital Group LLC boosted its holdings in LHC Group by 24.4% in the first quarter. Private Capital Group LLC now owns 1,116 shares of the health services provider’s stock valued at $124,000 after acquiring an additional 219 shares during the last quarter. Hedge funds and other institutional investors own 91.42% of the company’s stock.
LHC Group Company Profile
LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.